Saturday , December 16 2017
Home / Letter From The Editor (page 7)

Letter From The Editor

May 23, 2017

There has been a lot of press lately about the high cost of insulin, and even Congress has called the leaders of insulin companies to task for the prices. Some of the companies have linked up with discount programs like Blink to make insulin more affordable, and the companies themselves …

Read More »

May 20, 2017

I am sitting in the airport in Baltimore waiting to head back to Saint Petersburg. I was here to attend the PQA annual meeting. During this meeting, we heard from professional leaders as they discussed the progress that the Pharmacy Quality Assurance organization had made in ensuring better patient care …

Read More »

May 16, 2017

Last week our good friend from Diabetes Investor, David Kliff, provided us with his view on the future of insulin pumps, and all the companies that were trying to enter the market with their own pump. He seems to feel that in the long run the best product to use …

Read More »

May 13, 2017

This week, the Giro d’Italia started. This professional bike race stretches from the island of Sicily to the Alps and covers 2,250 miles of pedaling over 21 days. This Sunday, the Amgen Tour of California, America’s premier cycling event, begins and Team Novo Nordisk joins with 16 other professional teams …

Read More »

May 9, 2017

We have spent the better part of the last two months delving deep into the subject of Glucose metabolism in our Clinical Text. As we come to nearly the close of the author’s focus on Glycolysis, take a look to see how there may be new targets for diabetes and …

Read More »

May 6, 2017

Diabetes research can be a very fickle world at times. Over the years we have heard of many “cures” for type 1 diabetes. Most of the time the discoverer is someone not well known in the diabetes community and the work is dismissed as pie in the sky. This kind …

Read More »

May 2, 2017

We all make the assumption that insulin resistance comes from eating too much glucose. However, for many patients, this resistance occurs because they release too much insulin. This can be environmentally related or it can be blamed on heredity. Regardless of the cause, this hyperinsulinemia can result in long-lasting effects …

Read More »

April 29, 2017

The first line therapy for type 2 diabetes has long been metformin, and nowadays we are using it for patents who have prediabetes; it is also used “unofficially” by a lot of Weight Loss clinics. A lot of patients who are on metformin progress to insulin, and for many years …

Read More »

April 25, 2017

We all know of patients who walk around with glucose levels of 400mg/dl without any problems functioning. Most of our patients are often 100-200 points too high and they don’t even know it. When we start them on insulin, we usually go slow for fear of hypoglycemia, as often it …

Read More »

April 22, 2017

For many years, we never really gave great concern to the micro- and macrovascular problems in type 2 patients. Most of them were not diagnosed until they were in their late 50’s or early 60’s, and they did not really live long enough to develop severe problems. Now that diabetes …

Read More »